e-therapeutics integrates computational power and biological data to accelerate the discovery of life-transforming RNAi medicines.

Our GalOmic™ RNAi chemistry platform enables generation of specific, potent, and long-acting siRNA therapeutics for effective silencing of novel gene targets in the liver. The cutting-edge HepNet™ computational platform allows us to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development.  Leveraging the combined capabilities of HepNet™ and GalOmic™, we are progressing a therapeutic pipeline of highly differentiated RNAi candidates across a variety of therapeutic areas with high unmet need, including metabolic dysfunction-associated steatohepatitis (MASH) and dry age-related macular degeneration.  

The potential of e-therapeutics as a biotech company that fully integrates the latest advances in computation and artificial intelligence is clear, ultimately leading to the development of life-transforming RNAi medicines for patients.

Ali Mortazavi

Chief Executive Officer

AliMortazavi.jpg

Latest presentation

Corporate Presentation June 2024 Thumbnail.jpg

Annual Report

AR24 front_1280x720.jpg

Registered office:

Unit 4B, Level 4, 4 Kingdom Street, London W2 6PY 

For all investor enquiries, please contact:

Email: investorrelations@etherapeutics.co.uk

Following cancellation of admission of the Company’s ordinary shares to trading on AIM on 9 May 2024,
e-therapeutics' ordinary shares have been admitted onto the JP Jenkins share matching platform under the ticker: ETX

Shareholders wishing to trade these securities can do so through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.

The indicative pricing for the ordinary Shares (ISIN: GB00B2823H99), as well as the transaction history, is available on the JP Jenkins website at https://jpjenkins.com/company/e-therapeutics-plc/.

Bankers
Bank of Scotland
PO Box No 10
38 St. Andrew Square
Edinburgh
EH2 2AD
Tel: +44 (0) 131 465 3900
www.bankofscotland.co.uk

Registrars
Neville Registrars Limited
Neville House
18 Laurel Lane
Halesowen
West Midlands
B63 3DA
Tel: +44 (0) 121 585 1131
Fax: +44 (0) 121 585 1132
www.nevilleregistrars.co.uk

Auditors
Crowe U.K. LLP
55 Ludgate Hill
London
EC4M 7JW
www.crowe.com/uk

Solicitors
Stephenson Harwood LLP
1 Finsbury Circus
London
EC2M 7SH
Tel: +44 (0) 20 7329 4422
www.shlegal.com